B
Bull
Bull · 25%HKPD
$1.53
Precio del escenario
$0.347
-0.050 (-14.50%)Al cierre
Loading chart…
- High
- 0.400
- Open
- 0.391
- VWAP
- 0.36
- Vol
- 15.29K
- Mkt Cap
- —
- Low
- 0.344
- Amount
- 5.56K
- EV/EBITDA, TTM
- 0.00
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
AI analysis of Cellyan Biotechnology Co Ltd (HKPD)
sellGiven the current price of HKPD at $0.35 and a year-to-date change of -56.97%, it is not advisable to buy this asset right now. The RSI is at 33.28, indicating that the stock is oversold, but the negative momentum and declining performance over the past year (down 76.06%) raise serious concerns. Furthermore, the forward P/E ratio is at 0, suggesting a lack of expected earnings growth, and the gross margin has dropped to 10.32% in the latest quarter, which is significantly low. The primary risk is the recent compliance warning from Nasdaq, which could further depress the stock price if the company fails to meet the minimum bid price requirement.
Métricas de valoración
The current forward P/E ratio for Cellyan Biotechnology Co Ltd (HKPD) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for HKPD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
7.007-17NASDAQ.COMCellyan Biotechnology Receives Nasdaq Compliance Extension
8.507-16seekingalphaCellyan Biotechnology Secures Nasdaq Compliance Extension
- 8.501-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
7.001-16GlobenewswireCellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
- 9.012-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
HKPD FAQ — answered by Alphio AI
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.
Given the current price of HKPD at $0.35 and a year-to-date change of -56.97%, it is not advisable to buy this asset right now. The RSI is at 33.28, indicating that the stock is oversold, but the negative momentum and declining performance over the past year (down 76.06%) raise serious concerns. Furthermore, the forward P/E ratio is at 0, suggesting a lack of expected earnings growth, and the gross margin has dropped to 10.32% in the latest quarter, which is significantly low. The primary risk is the recent compliance warning from Nasdaq, which could further depress the stock price if the company fails to meet the minimum bid price requirement.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.